[go: up one dir, main page]

PT2655388T - Inibidores de glicosidase seletivos e as suas utilizações - Google Patents

Inibidores de glicosidase seletivos e as suas utilizações

Info

Publication number
PT2655388T
PT2655388T PT118507730T PT11850773T PT2655388T PT 2655388 T PT2655388 T PT 2655388T PT 118507730 T PT118507730 T PT 118507730T PT 11850773 T PT11850773 T PT 11850773T PT 2655388 T PT2655388 T PT 2655388T
Authority
PT
Portugal
Prior art keywords
glycosidase inhibitors
selective glycosidase
selective
inhibitors
glycosidase
Prior art date
Application number
PT118507730T
Other languages
English (en)
Inventor
Kaul Ramesh
J Mceachern Ernest
Mu Changwei
G Selnick Harold
J Vocadlo David
Wang Yaode
Wei Zhongyong
Zhou Yuanxi
Zhu Yongbao
Original Assignee
Merck Sharp & Dohme
Alectos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2011/074569 external-priority patent/WO2012159262A1/en
Application filed by Merck Sharp & Dohme, Alectos Therapeutics Inc filed Critical Merck Sharp & Dohme
Publication of PT2655388T publication Critical patent/PT2655388T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
PT118507730T 2010-12-23 2011-12-21 Inibidores de glicosidase seletivos e as suas utilizações PT2655388T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426773P 2010-12-23 2010-12-23
PCT/CN2011/074569 WO2012159262A1 (en) 2011-05-24 2011-05-24 Selective glycosidase inhibitors and uses thereof
US201161507684P 2011-07-14 2011-07-14

Publications (1)

Publication Number Publication Date
PT2655388T true PT2655388T (pt) 2016-09-06

Family

ID=46312954

Family Applications (1)

Application Number Title Priority Date Filing Date
PT118507730T PT2655388T (pt) 2010-12-23 2011-12-21 Inibidores de glicosidase seletivos e as suas utilizações

Country Status (26)

Country Link
US (2) US9243020B2 (pt)
EP (1) EP2655388B1 (pt)
JP (2) JP5861194B2 (pt)
KR (1) KR101979036B1 (pt)
CN (1) CN103339138B (pt)
AR (1) AR085004A1 (pt)
AU (1) AU2011349021B2 (pt)
BR (1) BR112013016179A2 (pt)
CA (1) CA2822493C (pt)
CO (1) CO6821931A2 (pt)
CY (1) CY1118157T1 (pt)
DK (1) DK2655388T3 (pt)
ES (1) ES2589164T3 (pt)
HR (1) HRP20161079T1 (pt)
HU (1) HUE030624T2 (pt)
IL (1) IL227055A (pt)
LT (1) LT2655388T (pt)
MX (1) MX343822B (pt)
MY (1) MY165728A (pt)
NZ (1) NZ612703A (pt)
PL (1) PL2655388T3 (pt)
PT (1) PT2655388T (pt)
RU (1) RU2609210C2 (pt)
TW (1) TWI572609B (pt)
WO (1) WO2012083435A1 (pt)
ZA (1) ZA201305531B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436687A1 (en) * 2005-03-01 2012-04-04 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
EP2322529B1 (en) 2006-08-31 2017-12-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
EP2321289A4 (en) * 2008-08-01 2011-11-16 Univ Fraser Simon SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2012061927A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
US9243020B2 (en) * 2010-12-23 2016-01-26 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2688899B1 (en) 2011-03-24 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2691407B1 (en) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2726468B1 (en) 2011-06-27 2017-04-12 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000086A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
RU2625308C2 (ru) * 2011-06-27 2017-07-13 Алектос Терапьютикс Инк. Селективные ингибиторы гликозидазы и их применение
SI2748171T1 (sl) 2011-08-25 2016-06-30 Merck Patent Gmbh Pirano (3,2-d)(1,3)tiazol kot inhibitorji glikozidaze
US9670195B2 (en) 2012-08-31 2017-06-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9809537B2 (en) 2012-08-31 2017-11-07 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
BR112015009638A2 (pt) * 2012-10-31 2017-07-04 Alectos Therapeutics Inc inibidores de glicosidase e usos dos mesmos
WO2014100934A1 (en) * 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
KR102043337B1 (ko) 2014-08-28 2019-11-11 아셰뉴론 에스아 글리코시다제 저해제
KR101777164B1 (ko) 2015-07-20 2017-09-11 순천향대학교 산학협력단 O-GlcNAc 트랜스퍼레즈 억제제용 UDP-GlcNAc의 C1-포스포네이트 유도체
US9994589B2 (en) * 2015-12-14 2018-06-12 Amicus Therapeutics, Inc. Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy
US10556902B2 (en) 2016-02-25 2020-02-11 Asceneuron Sa Glycosidase inhibitors
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
CN109071526B (zh) 2016-02-25 2023-02-28 阿森纽荣股份公司 哌嗪衍生物的酸加成盐
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
CN107814773B (zh) * 2017-11-13 2020-05-22 西安交通大学 含有喹唑啉酮的二芳基脲类化合物及其制备方法和应用
EP3810136A1 (en) * 2018-06-20 2021-04-28 Janssen Pharmaceutica NV Oga inhibitor compounds
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
MX2021002111A (es) * 2018-08-22 2021-07-16 Asceneuron S A Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa.
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
CA3138726A1 (en) * 2019-05-10 2020-11-19 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
CN111956656B (zh) * 2020-08-28 2021-10-15 河北大学 Oga抑制剂在制备抗肿瘤药物中的应用
WO2024083820A1 (en) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Method and composition for determining the level of o-glcnacylation in horses

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS423500Y1 (pt) 1964-02-29 1967-03-01
DE2632243C3 (de) 1976-07-17 1979-08-30 Heidelberger Druckmaschinen Ag, 6900 Heidelberg Auf variable Bogenlängen einstellbare Umführtrommel für Druckmaschinen
DE3620645A1 (de) 1985-12-20 1987-07-02 Bayer Ag 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung
EP0243686B1 (en) 1986-03-27 1992-07-15 Sumitomo Pharmaceuticals Company, Limited Beta-lactam compounds, and their production
SU1441749A1 (ru) * 1987-03-16 1996-01-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 2-АМИНО-5,5-ДИМЕТИЛ-4,5-ДИГИДРО-7Н-ПИРАНО [4,3-d] ТИАЗОЛ, ОБЛАДАЮЩИЙ ТРАНКВИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ
JPS6461459A (en) 1987-08-28 1989-03-08 Nippon Shinyaku Co Ltd Moranoline derivative
JPH01180894A (ja) 1988-01-07 1989-07-18 Wako Pure Chem Ind Ltd アミノ糖誘導体の新規な製造法
GB8900719D0 (en) 1989-01-13 1989-03-08 Nycomed As Compounds
US5079254A (en) 1990-06-04 1992-01-07 Merrell Dow Pharmaceuticals Inc. Derivatives of 6-aminooctahydroindolizinetriol
WO1992003415A1 (en) 1990-08-14 1992-03-05 Nova Pharmaceutical Corporation Protein kinase c modulators
US5276120A (en) 1991-05-30 1994-01-04 The Scripps Research Institute Process for forming omega-deuxy-azasugars
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5451679A (en) 1994-03-08 1995-09-19 G. D. Searle & Co. 2-chloro and 2-bromo derivatives of 1,5-iminosugars
JPH07316178A (ja) 1994-05-25 1995-12-05 Sankyo Co Ltd 糖アミノオキサゾリン類
CN1131672A (zh) 1994-11-22 1996-09-25 生化学工业株式会社 氨基环戊烷衍生物
EP1040827A3 (en) 1995-09-08 2000-10-11 Novo Nordisk A/S Use of 2-alkylpyrrolidines for the treatment of diabetes
CA2235415A1 (en) 1995-09-08 1997-03-13 Novo Nordisk A/S 2-alkylpyrrolidines
JPH09132585A (ja) 1995-11-10 1997-05-20 Shin Etsu Chem Co Ltd 新規アミノ糖及びキトオリゴ糖又はその類似オリゴ糖の製造方法
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
JPH11349541A (ja) 1998-06-08 1999-12-21 Sankyo Co Ltd アロサミゾリン誘導体の新規な中間体
GB9818732D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collection of compounds
US6774140B1 (en) 1999-05-11 2004-08-10 The Scripps Research Institute Iminocyclitol inhibitors of hexoaminidase and glycosidase
WO2000068194A1 (en) 1999-05-11 2000-11-16 The Scripps Research Institute Iminocyclitol inhibitors of hexoaminidase and glycosidase
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
EP1371733B1 (en) 2001-03-14 2011-05-11 Denki Kagaku Kogyo Kabushiki Kaisha Process for producing hyaluronic acid or its derivative
JP4233262B2 (ja) 2001-03-14 2009-03-04 生化学工業株式会社 カルバ糖アミン誘導体及びそれを用いるグリコシダーゼ阻害剤
WO2003008379A1 (en) 2001-06-08 2003-01-30 Mitsubishi Chemical Corporation Azasugar compounds
JP4866515B2 (ja) 2001-07-02 2012-02-01 生化学工業株式会社 糖オキサゾリン誘導体の製造方法
KR20040053100A (ko) 2001-07-24 2004-06-23 예일 유니버시티 키티나아제, 키티나아제 유사 분자 및 염증성 질환과관련된 방법, 조성물 및 키트
US20070066543A1 (en) 2003-05-22 2007-03-22 The Hospital For Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
CN1548053A (zh) 2003-05-23 2004-11-24 华晶基因技术有限公司 黄芩甙作为治疗焦虑症的药物的新用途
EP1664030A1 (en) 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
EP1713485A4 (en) 2004-01-20 2007-09-19 Optimer Pharmaceuticals Inc TREATMENT OF DEGENERATIVE TREATMENTS IN A MAMMALIAN WITH GLYCOSIDASE INHIBITORS
WO2006016904A2 (en) 2004-04-14 2006-02-16 Uab Research Foundation Activators of hexosamine biosynthesis as inhibitors of injury induced by ischemia or hemorrhagic shock
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20080096932A1 (en) 2004-07-23 2008-04-24 Darren Mansfield 3-Pyridinylethylcarboxamide Derivatives as Fungicides
US7335672B2 (en) 2004-09-13 2008-02-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7884115B2 (en) 2004-09-28 2011-02-08 Allergan, Inc. Methods and compositions for the treatment of pain and other neurological conditions
EP2436687A1 (en) 2005-03-01 2012-04-04 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
AT502145B1 (de) 2005-03-24 2012-01-15 Univ Graz Tech Glycosidase-hemmendes iminoalditol
US7820699B2 (en) 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
JP2009513603A (ja) 2005-10-26 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｃｈ拮抗活性を有する（ヘテロ）アリール化合物及びこの化合物を含む医薬
WO2007067515A2 (en) 2005-12-05 2007-06-14 Academia Sinica Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics
EP2322529B1 (en) 2006-08-31 2017-12-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
CN107253970A (zh) * 2006-08-31 2017-10-17 西蒙·弗雷瑟大学 选择性糖苷酶抑制剂及其用途
US8258307B2 (en) 2006-11-07 2012-09-04 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
EP2321289A4 (en) 2008-08-01 2011-11-16 Univ Fraser Simon SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
US8541441B2 (en) 2008-08-01 2013-09-24 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US20110195929A1 (en) 2008-08-05 2011-08-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010037207A1 (en) 2008-09-16 2010-04-08 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
AT507745B1 (de) 2008-12-16 2012-01-15 Forschungsholding Tu Graz Gmbh Fluorophile glykosidasehemmer
WO2011060397A1 (en) 2009-11-16 2011-05-19 Schering Corporation Substituted amino heterocycles useful as hiv antagonists
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2012061927A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
US8901087B2 (en) 2010-11-08 2014-12-02 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
WO2012061971A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
TW201249848A (en) * 2010-11-08 2012-12-16 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9243020B2 (en) 2010-12-23 2016-01-26 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
GB201103526D0 (en) 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof
CA2830882C (en) 2011-03-22 2021-03-16 Dinesh Barawkar Substituted fused tricyclic compounds, compositions and medicinal applications thereof
EP2688899B1 (en) 2011-03-24 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012129802A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof
EP2691407B1 (en) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2726468B1 (en) 2011-06-27 2017-04-12 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
RU2625308C2 (ru) 2011-06-27 2017-07-13 Алектос Терапьютикс Инк. Селективные ингибиторы гликозидазы и их применение
WO2013000086A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2744338B1 (en) 2011-08-18 2016-04-27 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
SI2748171T1 (sl) 2011-08-25 2016-06-30 Merck Patent Gmbh Pirano (3,2-d)(1,3)tiazol kot inhibitorji glikozidaze
BR112014027724B1 (pt) 2012-05-08 2022-05-03 Merck Sharp & Dohme Corp. E Alectos Therapeutics Inc Composto, e, composição farmacêutica
WO2014032184A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9809537B2 (en) 2012-08-31 2017-11-07 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9522883B2 (en) 2012-08-31 2016-12-20 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9670195B2 (en) 2012-08-31 2017-06-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
BR112015009638A2 (pt) 2012-10-31 2017-07-04 Alectos Therapeutics Inc inibidores de glicosidase e usos dos mesmos
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
PL2655388T3 (pl) 2016-12-30
EP2655388A4 (en) 2014-06-18
DK2655388T3 (en) 2016-09-19
US9815861B2 (en) 2017-11-14
CA2822493C (en) 2018-11-20
CY1118157T1 (el) 2017-06-28
WO2012083435A1 (en) 2012-06-28
ZA201305531B (en) 2014-10-29
CO6821931A2 (es) 2013-12-31
TW201249849A (en) 2012-12-16
JP5861194B2 (ja) 2016-02-16
HUE030624T2 (en) 2017-05-29
KR101979036B1 (ko) 2019-05-15
MX343822B (es) 2016-11-24
RU2013134345A (ru) 2015-01-27
JP2016033152A (ja) 2016-03-10
EP2655388B1 (en) 2016-06-08
BR112013016179A2 (pt) 2018-07-10
LT2655388T (lt) 2016-11-10
US9243020B2 (en) 2016-01-26
MY165728A (en) 2018-04-20
MX2013007434A (es) 2013-10-03
KR20140041406A (ko) 2014-04-04
AR085004A1 (es) 2013-07-24
CN103339138A (zh) 2013-10-02
US20140018309A1 (en) 2014-01-16
AU2011349021B2 (en) 2016-12-22
ES2589164T3 (es) 2016-11-10
RU2609210C2 (ru) 2017-01-31
JP6322177B2 (ja) 2018-05-09
TWI572609B (zh) 2017-03-01
HK1191016A1 (zh) 2014-07-18
JP2014501740A (ja) 2014-01-23
NZ612703A (en) 2015-07-31
EP2655388A1 (en) 2013-10-30
HRP20161079T1 (hr) 2016-10-21
US20160096858A1 (en) 2016-04-07
IL227055A (en) 2016-11-30
CN103339138B (zh) 2016-08-31
CA2822493A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
ZA201305531B (en) Selective glycosidase inhibitors and uses thereof
GB201103526D0 (en) Selective glycosidase inhibitors and uses thereof
IL249669A0 (en) Converted 5-fluoro-1h-pyrazolopyridines and their use
PT2592933T (pt) Inibidores de mif e suas utilizações
IL230917A0 (en) 1dyrk inhibitors and uses thereof
ZA201303776B (en) Bromodomain inhibitors and uses thereof
EP2606031A4 (en) AUTOTAXINE INHIBITORS AND APPLICATIONS THEREOF
EP2696682A4 (en) MIF-HEMMER AND USES THEREOF
PL2730564T3 (pl) Heterocykliczne aminy i ich zastosowania
IL226904A (en) Inganol-3-acetylates iii and Inganol-3-carbamates
IL221511A (en) Arilatriazolones associated with bis aryl and their use
ZA201208173B (en) Peptices and their use
ZA201302854B (en) Substituted benzamides and their uses
SI2655388T1 (sl) Selektivni inhibitorji glikozidaze
PL2651969T3 (pl) Standardy i inhibitory nieprzyjemnego zapachu
GB201203988D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203987D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203617D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203621D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203614D0 (en) Selective glycosidase inhibitors and uses thereof
IL214333A0 (en) Carbamoylphosphonates as inhibitors and uses thereof
GB201012144D0 (en) P13K inhibitors and uses thereof
GB201009704D0 (en) P13K inhibitors and uses thereof
GB201203984D0 (en) Selective glycosidase inhinitors and uses thereof
GB201018597D0 (en) Inhibitors